Javier M. C.
- Country
- Spain
- Department
- Oncology service
Research Overview
- Phase 1 Study of AMX-818 Monotherapy and Combination with Pembrolizumab in Advanced or Metastatic HER2-Expressing Cancers
- Phase 2 Randomized Trial of Neoadjuvant Pembrolizumab and Belzutifan with or without Lenvatinib in Patients with Localized Renal Cell Carcinoma
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Data & Insights
Has run more than one trial at 163 of 374 partner sites.
Specializations
Advanced Solid Tumor Oncology
The investigator concentrates on metastatic and treatment‑resistant solid cancers, emphasizing molecularly defined subpopulations and novel therapeutic combinations.
- Hormone Receptor‑Positive Breast Cancer
- Non‑Small Cell Lung Cancer with EGFR/ALK alterations
- Gastro‑esophageal Adenocarcinoma
- Renal Cell Carcinoma
- Colorectal Cancer with MSI‑H
Research integrates genomic profiling to guide targeted and immuno‑oncology strategies.
Hematologic Malignancies
In the hematology arena, the investigator addresses both acute and chronic blood cancers, focusing on innovative agents and transplant‑related approaches.
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Multiple Myeloma
- Diffuse Large B‑Cell Lymphoma
- Mantle Cell Lymphoma
Efforts include precision‑medicine trials and evaluation of post‑transplant immune modulation.
Immune‑Mediated and Autoimmune Disorders
The clinical portfolio extends to autoimmune conditions where dysregulated immunity drives pathology, supporting the development of targeted immunotherapies.
- Generalized Myasthenia Gravis
- Systemic Lupus Erythematosus
- IgA Nephropathy
- Bullous Pemphigoid
- Atopic Dermatitis
Studies often evaluate antibody‑targeted agents and cytokine‑blocking strategies.
Infectious and Pulmonary Diseases
Infectious disease research focuses on chronic lung infections and opportunistic pathogens, aiming to improve outcomes in immunocompromised populations.
- Nontuberculous Mycobacterial Lung Infection
- Pulmonary Tuberculosis
- Chronic Pulmonary Aspergillosis
- Clostridioides difficile Infection
- COVID‑19
Clinical work includes novel antimicrobial regimens and host‑directed therapies.
Cardiovascular and Metabolic Medicine
Cardiometabolic investigations address atherosclerotic disease, heart failure phenotypes, and metabolic liver disorders, with an emphasis on risk reduction and organ protection.
- Atherosclerotic Cardiovascular Disease
- Heart Failure with Preserved Ejection Fraction
- Acute Coronary Syndrome
- Type 2 Diabetes Mellitus
- Non‑Alcoholic Steatohepatitis
Efforts target novel lipid‑lowering agents, anti‑inflammatory pathways, and metabolic therapeutics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.